

## Appendix 1

### References

1. Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. Effective treatment of severe COVID-19 patients with tocilizumab. *Proc Natl Acad Sci U S A*. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29. PMID: 32350134; PMCID: PMC7245089.
2. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, Franceschini F, Airò P, Bazzani C, Beindorf EA, Berlendis M, Bezzi M, Bossini N, Castellano M, Cattaneo S, Cavazzana I, Contessi GB, Crippa M, Delbarba A, De Peri E, Faletti A, Filippini M, Filippini M, Frassi M, Gaggiotti M, Gorla R, Lanspa M, Lorenzotti S, Marino R, Maroldi R, Metra M, Matteelli A, Modena D, Moiola G, Montani G, Muiesan ML, Odolini S, Peli E, Pesenti S, Pezzoli MC, Pirola I, Pozzi A, Proto A, Rasulo FA, Renisi G, Ricci C, Rizzoni D, Romanelli G, Rossi M, Salvetti M, Scolari F, Signorini L, Taglietti M, Tomasoni G, Tomasoni LR, Turla F, Valsecchi A, Zani D, Zuccalà F, Zunica F, Focà E, Andreoli L, Latronico N. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. *Autoimmun Rev*. 2020 Jul;19(7):102568. doi: 10.1016/j.autrev.2020.102568. Epub 2020 May 3.
3. Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. *Clin Exp Rheumatol*. 2020:1-4. <http://www.ncbi.nlm.nih.gov/pubmed/32359035>
4. Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre

study on tocilizumab versus standard of care. *J Clin Virol.* 2020;(May):104444.

doi:10.1016/j.jcv.2020.104444

5. Morena V, Milazzo L, Oreni L, et al. European Journal of Internal Medicine Original article Off -label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in. *Eur J Intern Med.* 2020;(April):0-1. doi:10.1016/j.ejim.2020.05.011
6. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. *J Med Virol.* 2020:0-2. doi:10.1002/jmv.25801
7. Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. *Med Mal Infect.* 2020;(January). doi:10.1016/j.medmal.2020.05.001
8. Alberici F, Delbarba E, Manenti C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. *Kidney Int.* 2020;97(6):1083-1088
9. Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). *Microorganisms.* 2020;8(5). doi:10.3390/microorganisms8050695
10. Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. *Eur J Intern Med.* 2020;(April):1-5. doi:10.1016/j.ejim.2020.05.009
11. Campochiaro C, Della-torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. *Eur J Intern Med.* 2020. doi:10.1016/j.ejim.2020.05.021
12. Hassoun A, Thottacherry ED, Muklewicz J, Aziz QU, Edwards J. Utilizing tocilizumab

for the treatment of cytokine release syndrome in COVID-19 [published online ahead of print, 2020 May 16]. *J Clin Virol.* 2020;128:104443

13. Alattar R, Ibrahim TBH, Shaar SH, et al. Tocilizumab for the Treatment of Severe COVID-19. *J Med Virol.* 2020;(April). doi:10.1002/jmv.25964
14. Nafisa Wadud, Naim Ahmed, Mannu Mannu Shergil, Maida Khan, Murali G Krishna, Aamir Gilani, Samer El Zarif, Jodi Galaydick, Karthika Linga, Shravan Koor, Julia Galea, Lauren Stuczynski, Maria B Osundele. Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration. medRxiv 2020.05.13.20100081; doi: <https://doi.org/10.1101/2020.05.13.20100081>
15. Adrian Sanchez-Montalva, Julia Selares-Nadal, Juan Espinosa-Pereiro, Nuria Fernandez-Hidalgo, Santiago Perez-Hoyos, Fernando Salvador, Xavier Dura-Miralles, Marta Miarons, Andres Anton, Simeon Eremiev, Abiu Sempere-Gonzalez, Pau Bosch-Nicolau, Arnau Monforte-Pallares, Salvador Augustin, Julia Sampol, Alfredo Guillen-del-Castillo, Benito Almirante. Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study. medRxiv 2020.05.07.20094599; doi: <https://doi.org/10.1101/2020.05.07.20094599>.
16. Roumier M, Paule R, Vallée A, Rohmer J, Ballester M, Brun AL, Cerf C, Chabi ML, Chinet T, Colombier MA, Farfour E, Fourn E, Géri G, Khau D, Marroun I, Ponsoye M, Roux A, Salvator H, Schoindre Y, Si Larbi AG, Tchérakian C, Vasse M, Verrat A, Zuber B, Couderc LJ, Kahn JE, Groh M, Ackermann F; Foch COVID-19 Study Group. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis. *J Clin Immunol.* 2020 Nov 14:1–12. doi: 10.1007/s10875-020-00911-6. Epub ahead of print. PMID: 33188624.

17. Casey Allison Rimland, Camille E Morgan, Griffin J Bell, Min K Kim, Tanner Hedrick, Ashley Marx, Brian Bramson, Heidi Swygard, Sonia Napravnik, John L Schmitz, Shannon S Carson, William A Fischer, Joseph J Eron, Cynthia L Gay, Jonathan B Parr. Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center. medRxiv 2020.05.13.20100404; doi: <https://doi.org/10.1101/2020.05.13.20100404>.
18. Murali Ramaswamy, Praveen Mannam, Robert Comer, Emily Sinclair, Douglas Brent McQuaid, Monica L Schmidt. COVID-19 Disease in a Regional Community Health System: A Case-Control Study. medRxiv 2020.05.14.20099234; doi: <https://doi.org/10.1101/2020.05.14.20099234>.
19. Kimmig LM, Wu D, Gold M, Pettit NN, Pitrak D, Mueller J, Husain AN, Mutlu EA, Mutlu GM. IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections. *Front Med (Lausanne)*. 2020 Oct 28;7:583897. doi: [10.3389/fmed.2020.583897](https://doi.org/10.3389/fmed.2020.583897). PMID: 33195334.
20. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dillman NO, Frame D, Gregg KS, Kaul DR, Nagel J, Patel TS, Zhou S, Luring AS, Hanauer DA, Martin E, Sharma P, Fung CM, Pogue JM. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. *Clin Infect Dis*. 2020 Jul 11:ciaa954. doi: [10.1093/cid/ciaa954](https://doi.org/10.1093/cid/ciaa954). Epub ahead of print. PMID: 32651997.
21. Perrone F, Piccirillo MC, Ascierio PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C,

Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. *J Transl Med.* 2020 Oct 21;18(1):405. doi: 10.1186/s12967-020-02573-9. PMID: 33087150.

22. Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclair BA, Bednarz U, Marafelias M, Berry SM, Berry NS, Mathura S, Sawczuk IS, Biran N, Go RC, Sperber S, Piwoz JA, Balani B, Cicogna C, Sebti R, Zuckerman J, Rose KM, Tank L, Jacobs LG, Korcak J, Timmapuri SL, Underwood JP, Sugalski G, Barsky C, Varga DW, Asif A, Landolfi JC, Goldberg SL. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. *PLoS One.* 2020 Aug 13;15(8):e0237693. doi: 10.1371/journal.pone.0237693.
23. Sarah Heili-Frades, Pablo Minguez, Ignacio Mahillo-Fernandez, Tomas Prieto-Rumeau, Antonio Herrero Gonzalez, Lorena de la Fuente, Maria Jesus Rodriguez Nieto, German Peces-Barba Romero, Mario Peces-Barba, Maria del Pilar Carballosa de Miguel, Itziar Fernandez Ormaechea, Alba Naya Prieto, Farah Ezzine de Blas, Luis Jimenez Hiscock, Cesar Perez Calvo, Arnoldo Santos, Luis Enrique Munoz Alameda, Fredeswinda Romero Bueno, Miguel Gorgolas Hernandez-Mora, Alfonso Cabello Ubeda, Beatriz Alvarez Alvarez, Elizabet Petkova, Nerea Carrasco, Dolores Martin Rios, Nicolas Gonzalez Mangado, Olga Sanchez Pernaute. COVID-19 Outcomes in 4712 consecutively confirmed SARS-CoV2 cases in the city of Madrid. medRxiv 2020.05.22.20109850; doi: <https://doi.org/10.1101/2020.05.22.20109850>.
24. Ayerbe L, Risco C, Ayis S. The association between treatment with heparin and survival in patients with Covid-19. *J Thromb Thrombolysis* (2020). <https://doi.org/10.1007/s11239-020-02162-z>

25. Garibaldi BT, Fiksel J, Muschelli J, Robinson ML, Rouhizadeh M, Perin J, Schumock G, Nagy P, Gray JH, Malapati H, Ghobadi-Krueger M, Niessen TM, Kim BS, Hill PM, Ahmed MS, Dobkin ED, Blanding R, Abele J, Woods B, Harkness K, Thiemann DR, Bowring MG, Shah AB, Wang MC, Bandeen-Roche K, Rosen A, Zeger SL, Gupta A. Patient Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study. *Ann Intern Med.* 2020 Sep 22:M20-3905. doi: 10.7326/M20-3905. Epub ahead of print. Erratum in: *Ann Intern Med.* 2020 Nov 10;: PMID: 32960645.
26. Estela Moreno Garcia, Veronica Rico Caballero, Laia Albiach, Daiana Agüero, Juan Ambrosioni, Marta Bodro, Celia Cardozo, Mariana Chumbita, Lorena De la Mora, Nicole Garcia Pouton, Carolina Garcia Vidal, Ana GonzalezCordon, Marta Hernandez Meneses, Alexy Inciarte, Montse Laguno, Lorna Leal, Laura Linares, Irene Macaya, Fernanda Meira, Josep Mensa, Antonio Moreno, Laura Morata, Pedro Puerta Alcalde, Jhon Rojas, Montse Sola, Berta Torres, Manuel Torres, Adria Tome, Pedro Castro, Sara Fernandez, Josep Maria Nicolas, Alex Almuedo Riera, Jose Munoz, Mariana Jose Fernandez, Maria Angeles Marcos, Dolores Soy, Jose Antonio Martinez, Felipe Garcia, Alex Soriano. ocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. medRxiv 2020.06.05.20113738; doi: <https://doi.org/10.1101/2020.06.05.20113738>. T
27. Ana Fernández-Cruz, Belén Ruiz-Antorán, Ana Muñoz-Gómez, Aránzazu Sancho-López, Patricia Mills-Sánchez, Gustavo Adolfo Centeno-Soto, Silvia Blanco-Alonso, Laura Javaloyes-Garachana, Amy Galán-Gómez, Ángela Valencia-Alijo, Javier Gómez-Irusta, Concepción Payares-Herrera, Ignacio Morrás-Torre, Enrique Sánchez-Chica, Laura Delgado-Téllez-de-Cepeda, Alejandro Callejas-Díaz, Antonio Ramos-Martínez, Elena Múñez-Rubio, Cristina Avendaño-Solá on behalf of the

Puerta de Hierro COVID-19 Study Group. *Antimicrobial Agents and Chemotherapy* Aug 2020, 64 (9) e01168-20; DOI: 10.1128/AAC.01168-20

28. Issa N, Dumery M, Guisset O, Mourissoux G, Bonnet F, Camou F. Feasibility of tocilizumab in ICU patients with COVID-19. *J Med Virol*. 2020 Jun 2:10.1002/jmv.26110. doi: 10.1002/jmv.26110. Epub ahead of print. PMID: 32484915.
29. Borku Uysal B, Ikitimur H, Yavuzer S, Ikitimur B, Uysal H, Islamoglu MS, Ozcan E, Aktepe E, Yavuzer H, Cengiz M. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients. *J Med Virol*. 2020 Jun 2:10.1002/jmv.26111. doi: 10.1002/jmv.26111. Epub ahead of print. PMID: 32484930.
30. Ramon Perez Tanoira, Felipe Perez Garcia, Juan Romanyk, Peña Gomez-Herruz, Teresa Arroyo, Rosa Gonzalez, Lourdes Lledo Garcia, Cristina Verdu Exposito, Jose Sanz Moreno, Isabel Gutierrez, Abel Uribe Mathews, Esther Lopez Ramos, Lara Maceda Garcia, Daniel Troncoso, Juan Cuadros. Prevalence and risk factors for mortality related to COVID-19 in a severely affected area of Madrid, Spain. medRxiv 2020.05.25.20112912; doi: <https://doi.org/10.1101/2020.05.25.20112912>
31. Petrak RM, Skorodin NC, Van Hise NW, Fliegelman RM, Pinsky J, Didwania V, Anderson M, Diaz M, Shah K, Chundi VV, Hines DW, Harting BP, Sidwha K, Yu B, Brune P, Owaisi A, Beezhold D, Kent J, Vais D, Han A, Gowda N, Sahgal N, Silverman J, Stake J, Nepomuceno J, Heddurshetti R. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2. *Clin Transl Sci*. 2020 Sep 12. doi: 10.1111/cts.12894.
32. Rossi B, Nguyen LS, Zimmermann P, Boucenna F, Dubret L, Baucher L, Guillot H,

Bouldouyre MA, Allenbach Y, Salem JE, Barsoum P, Oufella A, Gros H. Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study. *Pharmaceuticals (Basel)*. 2020 Oct 17;13(10):317. doi: 10.3390/ph13100317. PMID: 33080877;

33. Martínez-Sanz J, Muriel A, Ron R, Herrera S, Pérez-Molina JA, Moreno S, Serrano-Villar S. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study. *Clin Microbiol Infect*. 2020 Sep 23:S1198-743X(20)30573-5. doi: 10.1016/j.cmi.2020.09.021. Epub ahead of print. PMID: 32979572.



# Appendix 2

